Asarfi Hospital Ltd (ASARFI) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Asarfi Hospital Ltd on NSE and BSE, with an AI summary of each filing.
We wish to inform you that CRISIL RATINGS LIMITED has upgraded the credit Rating of the Bank Facilities of Asarfi Hospital Limited.
Others (Uncategorized) · 09 Oct 2026, 4:16 am
CRISIL Upgrades Asarfi Hospital’s Long-Term Rating to 'CRISIL BBB/Stable' CRISIL Ratings upgraded Asarfi Hospital Limited’s long-term bank facilities rating to 'CRISIL BBB/Stable' from 'CRISIL BBB-/Stable' and assigned 'CRISIL A3+' for short-term facilities, covering enhanced bank debt of ₹60 crore (previously ₹46.5 crore). The upgrade reflects expanded operations, a 32% rise in ARPOB, higher cancer unit occupancy (42% in FY26 vs 30% in FY25), and stable operating margins of 20-21%. AHL reported FY26 revenue of ₹170.31 crore and PAT of ₹17.08 crore, supported by a healthy capital structure with gearing at 0.58x.
Summary Proceedings of 21ST Annual General Meeting of the Company held on Friday, 18th September''2026 Pursuant to Regulation 30 of the SEBI(Listing Obligations and Disclosure Requirements) ....
Annual General Meeting · 19 Sept 2026, 12:57 am
We hereby submit the Annual Report of Asarfi Hospital Limited for the Financial Year 2025-26, including the Notice convening the Annual General Meeting.
Others (Uncategorized) · 05 Sept 2026, 11:50 pm
We hereby inform you that the board of Director of the company at their meeting held on August 25, 2026 pursuant to the recommendation of the Audit Committee has approved the Appointment ....
Change in Auditor · 05 Sept 2026, 9:59 pm
Asarfi Hospital Appoints Ashutosh Kumar Sinha & Co as Cost Auditor The Board of Directors of Asarfi Hospital Limited, pursuant to the Audit Committee's recommendation, approved the appointment of Dhanbad-based M/s Ashutosh Kumar Sinha & Co, Cost Accountants (FRN: 004660), as the company's Cost Auditor on 25th Aug'26. The appointment complies with Section 148 of the Companies Act, 2013, covering the financial year FY27 (2026-27). The firm possesses extensive experience across cost audits, internal audits, and costing-based turnaround strategies. The company noted a delay in regulatory filing due to an inadvertent omission.
We hereby inform you that the meeting of the Board of Directors of Asarfi Hospital Limited was held on Tuesday, August 25, 2026 at 11:00 A.M. at the registered office of the Company at ....
Outcome · 26 Aug 2026, 12:53 am
Asarfi Hospital Board Approves Migration to BSE Main Board and NSE Listing The Board of Asarfi Hospital has approved the migration of the company from the BSE SME Platform to the BSE Main Board and a proposed listing on the NSE, subject to shareholder approval. The 21st Annual General Meeting (AGM) is scheduled for 18 Sep'26. The record date for e-voting eligibility is set for 11 Sep'26. Additionally, the board approved the re-appointment of Director Mr. Gopal Singh and the appointment of M/s Ashutosh Kumar Sinha & Co. as Cost Auditor for FY 2026-27.
Asarfi Hospital Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/08/2026 ,inter alia, to consider and approve Notice is hereby given that ....
Intimation · 19 Aug 2026, 4:34 am
Asarfi Hospital Board to Consider Migration to BSE Main Board & NSE Listing Asarfi Hospital's board will meet on 25-Aug-26 to consider a significant proposal for migrating from the BSE SME Platform to the BSE Main Board and a concurrent listing on the NSE. The agenda also includes approving the FY26 Directors' Report, fixing the date for the 21st AGM, and re-appointing Director Mr. Gopal Singh. Other key items are the appointment of a cost auditor for FY27 and setting the book closure/record date for the AGM, proposed for 05-Sep-26 to 18-Sep-26.
Submission of Newspaper Advertisement of unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2026.
Press Release · 08 Aug 2026, 7:20 pm
Asarfi Hospital Q1'FY27 Results: Strong Revenue and Profit Growth Asarfi Hospital reported strong Q1'FY27 results for the quarter ended 30 Jun'26. Consolidated revenue grew 33% YoY to ₹47.53 crore, while PAT increased 37% YoY to ₹4.27 crore. The performance was driven by improved patient volumes, higher realizations, and an enhanced case mix. EBITDA margin stood at 20% with PAT margin at 9%. Diluted EPS for the quarter was ₹2.17, up from ₹1.59 in the prior year period. IPD and OPD revenues grew 31% and 44% YoY, respectively, supported by strong performance in specialty services.
Intimation Under Regulation 30 of the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015- Submission of Press Release/ Media Release.
Press Release · 08 Aug 2026, 12:35 am
Asarfi Hospital Reports Strong Q1'FY27 Results with 33% Revenue Growth YoY Asarfi Hospital reported strong Q1'FY27 results for the quarter ended 30 Jun'26, with consolidated revenue growing 33% YoY to ₹47.5 Cr. EBITDA increased 34% YoY to ₹9.4 Cr, with a stable margin of 20%. Consolidated Profit After Tax (PAT) grew 37% YoY to ₹4.3 Cr, resulting in a PAT margin of 9%. The growth was driven by a 31% increase in IPD revenue and a 44% rise in OPD revenue, supported by higher patient volumes and improved Average Revenue Per Occupied Bed (ARPOB).
We hereby submit the Investor Presentation for the Qtr ended 30th June 2026.
Investor Presentation · 08 Aug 2026, 12:23 am
Asarfi Hospital Reports Strong Q1'FY27 Driven by Operational Performance Asarfi Hospital reported strong Q1'FY27 results, with consolidated revenue rising 33.2% YoY to ₹47.5 Cr and PAT up 36.7% YoY to ₹4.3 Cr. EBITDA grew 35.3% to ₹9.5 Cr, with the margin expanding to 19.9% from 19.6%. Operational metrics showed strength, as Super-Specialty ARPOB increased to ₹23,498. The Cancer Unit saw a notable occupancy jump to 56% from 42% YoY, and its ARPOB increased to ₹31,892. Total bed capacity in the Super-Specialty unit was increased to 285 from 250.
We wish to inform you that the board of Director of Asarfi Hospital Limited at its meeting held today, i.e, 07 August 2026, has considered and approved the unaudited standalone and consolidated ....
Financial Result · 08 Aug 2026, 12:10 am
Asarfi Hospital Reports Strong Q1 FY27 Standalone Profit Growth Asarfi Hospital Limited reported standalone results for the quarter ended 30 Jun'26. Revenue from operations grew 32.75% YoY to ₹4,734.47 lakhs. Profit After Tax (PAT) increased by 33.54% YoY to ₹426.84 lakhs from ₹319.64 lakhs in the corresponding prior year quarter. Sequentially, revenue grew 5.13% and PAT increased by 4.28%. Basic Earnings Per Share (EPS) for the quarter stood at ₹2.17, up from ₹1.62 YoY and ₹2.08 QoQ. The board approved these unaudited financial results on 07 Aug'26.
We wish to inform you that the Board of Directors of Asarfi Hospital Limited ("the Company"), at its meeting held today, i.e., 07 August 2026, has considered and approved the Unaudited ....
Outcome · 08 Aug 2026, 12:01 am
Asarfi Hospital Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 4,753 (+33.2% YoY | +5.1% QoQ) ■ EBITDA: 946 (+35.3% YoY | +22.5% QoQ) ■ EBITDA Margin (%): 19.9 (+31 bps YoY | +284 bps QoQ) ■ PAT: 427 (+36.7% YoY | +8.9% QoQ) ■ EPS (INR): 2.17 (+36.5% YoY | +9.0% QoQ)
Asarfi Hospital Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve of the Unaudited Financial ....
Intimation · 07 Aug 2026, 5:30 am
Asarfi Hospital Board Meeting to Approve Q1 FY27 Results Asarfi Hospital Limited has scheduled its 3rd Board of Directors meeting for FY 2026-27 on 7th Aug'26. The primary agenda is the consideration and approval of the Unaudited Financial Results for the quarter ended 30th Jun'26. The meeting will also consider the Limited Review Report from its statutory auditors, M/s R. K. Thakkar & Co.
We wish you to inform you that the management of Asarfi Hospital Limited Participated in Analyst/ Investor Webinar held on 24th July'' 2026 from 04:30 PM to 5:30 PM (IST).
Others (Uncategorized) · 28 Jul 2026, 1:17 am
Asarfi Hospital Reiterates Growth Targets, Eyes Main Board Migration Asarfi Hospital's management reiterated its ₹400 crore revenue target by FY28 at its investor webinar on 24 Jul'26. Key growth drivers identified are cardiology, oncology, and neurosurgery. Strategic initiatives include bidding for a 100-seat medical college under a PPP model and a proposed Bone Marrow Transplant facility. The company is also preparing for a Main Board migration and evaluating the acquisition of a 70-bed hospital to expand its regional presence, highlighting a multi-pronged growth and expansion strategy.
we wish to inform you that the Company will participate in an Analyst/Institutional Investor Meeting on dated July 24, 2026.
Intimation · 17 Jul 2026, 2:02 am
Asarfi Hospital Schedules Virtual Analyst Meeting for July 24, 2026 Asarfi Hospital Limited (BSE: 543943) has scheduled a virtual Analyst/Institutional Investor meeting on Jul 24, 2026, from 4:30 PM to 5:30 PM IST. The meeting is organized by Hem Securities Ltd. Discussions will be based on the investor presentation for the quarter and year ended Mar 31, 2026. The company noted the schedule is subject to potential changes.
We wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Saturday, 27 June 2026, commenced at 3:00 P.M. and concluded at 7:30 P.M., inter alia, considered ....
Others (Uncategorized) · 28 Jun 2026, 1:18 am
Asarfi Hospital Board Approves Bid for Jharkhand PPP Medical College Project Asarfi Hospital's board, at its meeting on 27 Jun'26, approved participation in a Request for Proposal (RFP) for a Public-Private Partnership (PPP) project in Jharkhand. The project involves operating and augmenting a 100-bed district hospital in Dhanbad into a medical college with an intake of at least 100 MBBS students. The board also approved furnishing a refundable Bid Security of Rs. 3.52 Crores for the proposal. The approval is solely for participation in the bidding process and does not imply project award.
We wish you to inform you for the year ended March 31, 2026, There was no material deviation in the use of proceeds of issue of 5180000 Equity Share of face value of Rs.10 each, aggregating ....
Others (Uncategorized) · 30 May 2026, 6:05 pm
Asarfi Hospital Reports No Deviation in IPO Proceeds Utilization for FY26 Asarfi Hospital Limited (Scrip: 543943) confirmed no material deviation or variation in the use of its IPO proceeds for the year ended 31st Mar'26. The company had raised Rs. 26.94 crore through its public issue on 26th Jul'23. Funds were fully utilized as per the offer document's stated objectives, which included capital expenditure for a cancer hospital (Rs. 12.21 crore), acquiring land (Rs. 7.65 crore), issue expenses (Rs. 3.83 crore), and general corporate purposes (Rs. 3.23 crore).
We hereby submit the transcript of the earning conference call held on May 27, 2026, wherein the Audited standalone and consolidated Financial Results of the company for the Qtr4 & Year ....
Transcript · 30 May 2026, 4:51 pm
Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation of our intimation dated May 21, 2026 regarding the schedule ....
Audio / Video · 27 May 2026, 11:22 pm
Asarfi Hospital Management Participates in Virtual Investor Meet Asarfi Hospital Limited management participated in a one-to-one virtual investor meet organized by Chorus Call Conferencing Services on 27 May'26. The company was represented by its Managing Director, CFO, and Chief Manager of Finance. Asarfi Hospital confirmed that only publicly available information was discussed and no Unpublished Price Sensitive Information (UPSI) was shared with institutional investors or analysts during the meeting. A recording is available via the provided link.
With reference to our earlier intimation regarding the Analyst / Investor Meeting scheduled to be held on Monday, May 25, 2026, at 04:00 P.M. (IST), we wish to inform you that due to unavoidable ....
Intimation · 27 May 2026, 4:00 pm
Asarfi Hospital Reschedules Q4 & FY26 Results Analyst Call Asarfi Hospital (BSE: 543943) has rescheduled its analyst and investor meeting to discuss audited financial results for the quarter and year ended Mar 31, '26. The meeting, originally set for May 25, '26, will now take place on Wed, May 27, '26, at 04:00 PM IST. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the call. The rescheduling was attributed to unavoidable reasons.
We wish to inform you that the Company has scheduled a Conference Call with Analysts / Investors on Monday, May 25, 2026 at 04:00 P.M. (IST), inter alia, to discuss the Audited Financial ....
Intimation · 25 May 2026, 4:00 pm
We herewith a press release titled Extract of Audited Standalone and Consolidated financial Results of the Quarter and Year Ended March''31,2026 for your kind information and record.
Press Release · 12 May 2026, 7:15 pm
Asarfi Hospital Reports Strong FY26 Growth and Margin Expansion Asarfi Hospital's consolidated FY26 revenue grew 42% YoY to ₹173.5 Cr, with EBITDA up 42% to ₹35.3 Cr and PAT increasing 58% YoY to ₹16.7 Cr. EBITDA and PAT margins stood at 20% and 10%, respectively. Growth was driven by improved ARPOB, better realizations, and a stronger case mix. For Q4 FY26, consolidated revenue was ₹45.2 Cr, with PAT at ₹3.9 Cr. The Board approved these audited results on 11 May'26. The full-year consolidated EPS for FY26 was ₹8.47, up from ₹5.37 in FY25.
We herewith a press release titled Extract of Audited Standalone and Consolidated financial Results of the Quarter and Year Ended March''31,2026 for your kind information and record.
Press Release · 12 May 2026, 7:14 pm
Asarfi Hospital Reports Strong FY26 Results with 42% Revenue Growth and Margin Expansion Asarfi Hospital reported strong FY26 results with consolidated revenue growing 42% YoY to ₹173.5 Cr and PAT surging 58% YoY to ₹16.7 Cr. EBITDA margin expanded to 20%, driven by higher patient volumes, improved Average Revenue Per Occupied Bed (ARPOB), and an enhanced specialty mix. For Q4FY26, consolidated revenue was ₹452.4 Cr, and PAT stood at ₹39.2 Cr. The Board has recommended an EPS of ₹8.47 for FY26, up from ₹5.37 in FY25. The results were approved by the Board on 11 May'26.
Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 15 - Press Release Titled Extract of Audited Standalone and Consolidated Financial Results ....
Press Release · 12 May 2026, 12:09 am
Asarfi Hospital Posts Strong FY26 Results with 58% PAT Growth Asarfi Hospital reported robust FY26 performance, with revenue growing 42% YoY to ₹173.5 Cr and PAT increasing 58% YoY to ₹16.7 Cr. The consolidated net profit for the year ended 31 Mar'26 stood at ₹16.66 Cr, up from ₹10.58 Cr in FY25. For Q4 FY26, consolidated PAT was ₹3.92 Cr versus ₹3.59 Cr YoY. Growth was driven by higher patient volumes, improved ARPOB, and a better case mix in high-acuity specialties like cardiology and oncology. EBITDA margins were stable at 20%, while ROCE improved to 17%.
Investor Presentation of Asarfi Hospital Limited for the Quarter and Financial Year ended 31st March, 2026.
Investor Presentation · 11 May 2026, 11:58 pm
Asarfi Hospital Q4'FY26: Strong Revenue Growth Offset by Margin Compression Asarfi Hospital reported Q4'FY26 consolidated revenue of Rs 45.2 Cr (+29% YoY), driven by a 54% YoY increase in IPD revenues. EBITDA grew 23% YoY to Rs 7.7 Cr, while PAT increased 9% YoY to Rs 3.9 Cr. EBITDA and PAT margins compressed to 17% and 9% respectively, down from 18% and 10% in Q4'FY25. A decline in medical and surgical oncology revenues, linked to lower volumes and government reimbursement delays, impacted performance. Super-specialty ARPOB grew 24% YoY, while cancer unit occupancy rose to 40%.
We wish to inform you that the Board of Director of Asarfi Hospital Limited at its meeting held today i.e, Monday 11th May 2026, has inter alia considered and approved the standalone and ....
Financial Result · 11 May 2026, 11:46 pm
Asarfi Hospital Limited - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakhs) ■ Revenue: 4524 (+28.9% YoY | -3.5% QoQ) ■ EBITDA: 772 (+22.8% YoY | -29.2% QoQ) ■ EBITDA Margin (%): 17.1 (-84 bps YoY | -619 bps QoQ) ■ PAT: 392 (+9.2% YoY | -27.8% QoQ) ■ EPS (INR): 1.99 (+9.3% YoY | -27.9% QoQ)